Amarantus Bioscience Holdings Inc (AMBS)

[MUKA1]

Interesting new MJF article in AARP magazine
https://www.michaeljfox.org/foundation/news-detail.php?michael-fox-kicks-off-parkinson-awareness-month-with-the-april-issue-of-aarp-the-magazine

Statement is made that:
"At the moment, all eyes are on a promising surgical therapy involving a specialized brain protein called neurturin, which may slow or stop Parkinson's symptoms rather than temporarily mask them. In testing, neurturin has been found to help rejuvenate neurons damaged by Parkinson's, and restore function."

Neurturin belongs to the to the GDNF family and has been in study for longer than MANF.... and has received MJFF grants back to at least 2005, whereas MANF is newer to the game and has only been on the MJFF radar since 2010.

IMO the ceregene results will be an immense predictor for the success of MANF. The GDNF derived Cogaine failed to show measurable behavioral improvement to go with their clinical improvement……but, this is attributed to it being an orally administered drug. The administration of neurturin is surgical, as I assume?? MANF would be.(correct me if wrong?)

AMBS recently released results for both protection and reinnervation have shown that MANF yields significantly better results than those of the GDNF family.
I would expect that positive news for neurturin, being released in April, could be a huge catalyst for MANF in the eyes of science.